ArticleFrontiers in pharmacology2018

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial.

Carlo Buonerba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.